CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement

Byung Woog Kang, Joon Ho Moon, Yee Soo Chae, Soo Jung Lee, Jong Gwang Kim, Yeo-Kyeoung Kim, Je-Jung Lee, Deok-Hwan Yang, Hyeoung-Joon Kim, Jin Young Kim, Young Rok Do, Keon Uk Park, Hong Suk Song, Ki Young Kwon, Min Kyung Kim, Kyung Hee Lee, Myung Soo Hyun, Hun Mo Ryoo, Sung Hwa Bae, Hwak Kim, Sang Kyun Sohn

Cancer Research and Treatment. 2013;45(2):112-117. Published online 2013 June 30 DOI: https://doi.org/10.4143/crt.2013.45.2.112

Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study

Ofir Wolach, Abigail Fraser, Michael Luchiansky, Chava Shapiro, Judith Radnay, Ofer Shpilberg, Michael Lishner, Meir Lahav

Hematological Oncology. 2014;33(1):42-47

Link1

Long-term impact of prior rituximab therapy and early lymphocyte recovery on auto-SCT outcome for diffuse large B-cell lymphoma

D G Stover, V K Reddy, Y Shyr, B N Savani, N Reddy

Bone Marrow Transplantation. 2011;47(1):82-87

Link1

Link2 Link3

Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement

Cancer Research and Treatment. 2013;45(2):112-117

Link1

Link2

Rituximab

Reactions Weekly. 2017;1659(1):269-269

Link1

Link2 Link3

Comparison of outcomes after auto-SCT for patients with relapsed diffuse large B-cell lymphoma according to previous therapy with rituximab

S D Smith, B J Bolwell, L A Rybicki, T Kang, R Dean, A Advani, S Thakkar, R Sobecks, M Kalaycio, B Pohlman, J W Sweetenham

Bone Marrow Transplantation. 2010;46(2):262-266

Link1

Link2 Link3

Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma

Talha Badar, Bryon D. Johnson, Mehdi Hamadani

Bone Marrow Transplantation. 2020;

Link1

Link2 Link3

Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome

Samo Rozman, Iztok Grabnar, Srdjan Novaković, Ales Mrhar, Barbara Jezeršek Novaković

British Journal of Clinical Pharmacology. 2017;83(8):1782-1790

Link1 Link2

Increased bone marrow FDG uptake at PET/CT is not a sufficient proof of bone marrow involvement in diffuse large B-cell lymphoma

Hugo J.A. Adams, Thomas C. Kwee

American Journal of Hematology. 2015;90(9):E182-E182

Link1 Link2 Link3

Involvement of bone marrow with intravascular large B-cell lymphoma

Raihan Sajid, Adnan Qureshi

Hematology/Oncology and Stem Cell Therapy. 2010;3(1):39-41

Link1 Link2

Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy

D. Ennishi, M. Yokoyama, Y. Terui, H. Asai, S. Sakajiri, Y. Mishima, S. Takahashi, H. Komatsu, K. Ikeda, K. Takeuchi, M. Tanimoto, K. Hatake

Annals of Oncology. 2009;20(3):526-533

Link1 Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.